Breaking News, Financial News

Charles River 4Q Financial Results

Acquisition of Explora BioLabs and robust performance in the DSA segment, contribute to fourth-quarter revenue growth.

Charles River 4Q Revenues: $1.10 billion (+21%) 4Q Earnings: $187.4 million (+36%) FY Revenues: $3.98 billion (+12%) FY Earnings: $492.6 million (+24%) Comments: The addition of a 53rd week at the end of 2022, contributed approximately 5.8% to reported fourth-quarter revenue growth. The acquisition of Explora BioLabs contributed 1.8% to consolidated fourth-quarter revenue growth, and the divestitures of the Research Models and Services operations in Japan (RMS Japan) and the CDMO site in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters